GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » 14-Day RSI

PCI Biotech Holding ASA (OSL:PCIB) 14-Day RSI : 45.75 (As of Dec. 11, 2024)


View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA 14-Day RSI?

The Relative Strength Index (RSI) is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100. Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30.

As of today (2024-12-11), PCI Biotech Holding ASA's 14-Day RSI is 45.75.

The industry rank for PCI Biotech Holding ASA's 14-Day RSI or its related term are showing as below:

OSL:PCIB's 14-Day RSI is ranked better than
55.48% of 1523 companies
in the Biotechnology industry
Industry Median: 46.92 vs OSL:PCIB: 45.75

Competitive Comparison of PCI Biotech Holding ASA's 14-Day RSI

For the Biotechnology subindustry, PCI Biotech Holding ASA's 14-Day RSI, along with its competitors' market caps and 14-Day RSI data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


PCI Biotech Holding ASA's 14-Day RSI Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, PCI Biotech Holding ASA's 14-Day RSI distribution charts can be found below:

* The bar in red indicates where PCI Biotech Holding ASA's 14-Day RSI falls into.



PCI Biotech Holding ASA  (OSL:PCIB) 14-Day RSI Calculation

The formula for calculating RSI is:

RSI=100[ 100 / ( 1 + Average Gain / Average Loss )]

* Note that the formula uses a positive value for the average loss.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


PCI Biotech Holding ASA  (OSL:PCIB) 14-Day RSI Explanation

The Relative Strength Index (RSI), developed by J. Welles Wilder in his book “New Concepts in Technical Trading Systems.”, is a momentum oscillator that measures the speed and change of price movements. The RSI is most typically used on a 14-day period, measured on a scale from 0 to 100.

Traditionally, an asset is considered overbought or overvalued when the RSI is above 70 and oversold or undervalued when it is below 30. A RSI surpasses the 30 level indicates a bullish sign, when it slides below 70 level, it’s a bearish sign. This level can be adjusted depending on the security’s pattern and the market’s underlying trend. In an uptrend or bullish market, the RSI might range within a higher interval, investors could set the support level higher. If a downtrend or bearish market occurs, investors may need to lower the resistance level.

RSI can also be used in trading techniques to indicate the trading signal, such as Divergences and Swing Rejections.


PCI Biotech Holding ASA 14-Day RSI Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's 14-Day RSI provided by GuruFocus.com. Please click on the following links to see related term pages.


PCI Biotech Holding ASA Business Description

Traded in Other Exchanges
Address
Ullernchausseen 64, Oslo, NOR, N-0379
PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines